December 4, 2023 Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research Read More
December 1, 2023 Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model Read More
November 24, 2023 Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option Read More
November 21, 2023 Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants Read More
November 14, 2023 Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update Read More
October 4, 2023 Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease Read More
September 25, 2023 Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023 Read More
September 20, 2023 Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference Read More
September 12, 2023 Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia Read More
August 28, 2023 Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model Read More
August 10, 2023 Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update Read More
August 7, 2023 Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders® Read More
July 31, 2023 Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference Read More
May 12, 2023 Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update Read More
May 3, 2023 Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease Read More
March 29, 2023 Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting Read More
March 23, 2023 Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update Read More
March 22, 2023 Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders Read More
March 21, 2023 Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program Read More
March 9, 2023 Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference Read More
February 27, 2023 Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium Read More
February 2, 2023 Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences Read More
January 12, 2023 Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference Read More
